JP7084389B2 - Ｄｈｏｄｈの阻害剤として有用な２，４，５－三置換１，２，４－トリアゾロン - Google Patents

Ｄｈｏｄｈの阻害剤として有用な２，４，５－三置換１，２，４－トリアゾロン Download PDF

Info

Publication number
JP7084389B2
JP7084389B2 JP2019522859A JP2019522859A JP7084389B2 JP 7084389 B2 JP7084389 B2 JP 7084389B2 JP 2019522859 A JP2019522859 A JP 2019522859A JP 2019522859 A JP2019522859 A JP 2019522859A JP 7084389 B2 JP7084389 B2 JP 7084389B2
Authority
JP
Japan
Prior art keywords
alkyl
group
fluoro
groups
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019522859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533694A (ja
JP2019533694A5 (enExample
Inventor
シュテファン・ニコラウス・グラートル
デュイ・グエン
クヌート・アイス
ユディット・ギュンター
ティモ・シュテルフェルト
アンドレアス・ヤンツァー
ズヴェン・クリスティアン
トーマス・ミュラー
シェリフ・エル・シェイク
ハン・ジエ・ジョウ
チャンジア・ジャオ
デイヴィッド・ブライアン・サイクス
スティーヴン・ジェームズ・フェラーラ
ケリー・リュウ
ミヒャエル・クレーバー
クラウディア・メルツ
ミヒャエル・ニーフス
マルティーナ・シェーファー
カチャ・ツィマーマン
カール・フリードリッヒ・ニジング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of JP2019533694A publication Critical patent/JP2019533694A/ja
Publication of JP2019533694A5 publication Critical patent/JP2019533694A5/ja
Application granted granted Critical
Publication of JP7084389B2 publication Critical patent/JP7084389B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2019522859A 2016-10-27 2017-10-25 Ｄｈｏｄｈの阻害剤として有用な２，４，５－三置換１，２，４－トリアゾロン Active JP7084389B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/103643 2016-10-27
CNPCT/CN2016/103643 2016-10-27
US201762569296P 2017-10-06 2017-10-06
US62/569,296 2017-10-06
PCT/EP2017/077252 WO2018077923A1 (en) 2016-10-27 2017-10-25 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh

Publications (3)

Publication Number Publication Date
JP2019533694A JP2019533694A (ja) 2019-11-21
JP2019533694A5 JP2019533694A5 (enExample) 2020-12-03
JP7084389B2 true JP7084389B2 (ja) 2022-06-14

Family

ID=60164720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522859A Active JP7084389B2 (ja) 2016-10-27 2017-10-25 Ｄｈｏｄｈの阻害剤として有用な２，４，５－三置換１，２，４－トリアゾロン

Country Status (26)

Country Link
US (4) US10815215B2 (enExample)
EP (1) EP3532468B1 (enExample)
JP (1) JP7084389B2 (enExample)
KR (1) KR20190084954A (enExample)
CN (2) CN115557907B (enExample)
AU (1) AU2017351688B2 (enExample)
BR (1) BR112019008458A2 (enExample)
CA (1) CA3041643A1 (enExample)
CL (1) CL2019001160A1 (enExample)
CO (1) CO2019004137A2 (enExample)
CR (1) CR20190212A (enExample)
CU (1) CU24572B1 (enExample)
DO (1) DOP2019000110A (enExample)
EC (1) ECSP19030002A (enExample)
GE (1) GEP20217248B (enExample)
IL (1) IL266214B (enExample)
JO (1) JOP20190094A1 (enExample)
MX (1) MX382665B (enExample)
NI (1) NI201900041A (enExample)
PE (1) PE20191005A1 (enExample)
PH (1) PH12019500932A1 (enExample)
TN (1) TN2019000136A1 (enExample)
TW (1) TW201827414A (enExample)
UA (1) UA123688C2 (enExample)
UY (1) UY37461A (enExample)
WO (1) WO2018077923A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
US10968216B2 (en) * 2016-10-27 2021-04-06 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
CA3060390A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
EP3553052A1 (en) * 2018-04-10 2019-10-16 Bayer AG 5-oxo-4,5-dihydro-1h-1,2,4-triazol derivatives for the treatment of cancer
TW201945346A (zh) 2018-04-10 2019-12-01 德商拜耳廠股份有限公司 2,4,5-三取代的1,2,4-三唑酮之製備方法
WO2019197269A1 (en) * 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
EP3858361B1 (en) 2018-09-28 2025-10-08 FUJIFILM Corporation Antitumor agent containing cytarabine, antitumor effect enhancer used in combination with cytarabine, antitumor kit, and antitumor agent used in combination with cytarabine
BR112021012305A2 (pt) 2018-12-21 2021-10-05 Les Laboratoires Servier Sas Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas
TW202043208A (zh) * 2019-01-11 2020-12-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
MX2021009521A (es) * 2019-02-07 2021-09-08 Janssen Biotech Inc Inhibidores de dihidroorotato deshidrogenasa.
TW202104207A (zh) * 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
EP3750892A1 (en) 2019-06-14 2020-12-16 Yerevan State University Novel 5-cyclopropyl-furo[3,4-c]pyridine-3,4(1h,5h)-dione 1,1' substituted derivatives and their uses
AU2020338985A1 (en) * 2019-08-29 2022-04-14 Janssen Biotech, Inc. Substituted urea dihydroorotate dehydrogenase inhibitors
CN114630822B (zh) * 2019-10-10 2024-10-01 詹森生物科技公司 联芳基二氢乳清酸脱氢酶抑制剂
CN114222732B (zh) * 2019-10-28 2023-04-04 南京明德新药研发有限公司 一种尿酸促排剂及其合成方法和其在医药上的应用
EP4100124A1 (en) * 2020-02-04 2022-12-14 Janssen Biotech, Inc. Heterocyclic compounds as dihydroorotate dehydrogenase inhibitors
EP3912627B1 (en) 2020-05-20 2022-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of coronavirus infections
WO2021240423A1 (en) * 2020-05-29 2021-12-02 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
WO2021240424A1 (en) 2020-05-29 2021-12-02 Janssen Biotech, Inc. Indazole and benzoisoxazole dihydroorotate dehydrogenase inhibitors
EP4166551A4 (en) * 2020-05-29 2024-07-10 Medshine Discovery Inc. Triazolone compound
WO2021240429A1 (en) 2020-05-29 2021-12-02 Janssen Biotech, Inc. Benzofuran and benzopyran dihydroorotate dehydrogenase inhibitors
JP2023535346A (ja) * 2020-07-14 2023-08-17 ナンジン ゼンシャイン ファーマシューティカルズ カンパニー リミテッド Ｄｈｏｄｈ阻害剤としての化合物
CN111773214B (zh) * 2020-07-17 2021-04-20 中国人民解放军军事科学院军事医学研究院 2,4,5-三取代的1,2,4-三唑酮在制备抗病毒药物中的用途
EP3960170A1 (en) 2020-08-25 2022-03-02 Bayer AG Dosing schedule for a method of treatment with dhodh inhibitors
GB2598624A (en) * 2020-09-07 2022-03-09 Lorico Aurelio Use of triazole analogues for inhibition of a tripartite VOR protein complex in multicellular organisms
CN116249702B (zh) * 2020-09-28 2025-04-25 微境生物医药科技(上海)有限公司 用作dhodh抑制剂的1,2,4-三唑酮衍生物
WO2022070071A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
WO2022070069A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
WO2022167402A1 (en) 2021-02-02 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of therapy comprising administering a therapeutically effective combination comprising a dhodh inhibitor and an idh inhibitor
WO2023280181A1 (zh) * 2021-07-05 2023-01-12 微境生物医药科技(上海)有限公司 用作dhodh抑制剂的1,2,4-三唑酮衍生物及其制备方法和用途
CN118284603A (zh) * 2021-11-26 2024-07-02 南京明德新药研发有限公司 三氮唑酮类化合物的晶型及其应用
KR102686544B1 (ko) * 2023-12-04 2024-07-19 대한민국 Bay-2402234을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물
WO2025202415A1 (en) 2024-03-28 2025-10-02 Institut National de la Santé et de la Recherche Médicale Dhodh inhibitors for use in the chronopharmacoligical treatment and prevention of obesity and obesity-related metabolic disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103006645A (zh) 2011-09-27 2013-04-03 华东理工大学 2-氨基苯并噻唑衍生物作为dhodh抑制剂的应用
JP2015523353A (ja) 2012-06-15 2015-08-13 グレンマーク・ファーマシューティカルズ・エスエー ｍＰＧＥＳ−１阻害剤としてのトリアゾロン化合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098896A (en) 1975-09-29 1978-07-04 Chevron Research Company 1-Halohydrocarbylthio-3-hydrocarbylthio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4237140A (en) * 1979-05-18 1980-12-02 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetaminophen
DE3936623A1 (de) 1989-11-03 1991-05-08 Bayer Ag Sulfonylaminocarbonyltriazolinone mit ueber schwefel gebundenen substituenten
DE3934081A1 (de) 1989-10-12 1991-04-18 Bayer Ag Sulfonylaminocarbonyltriazolinone
DE3936622A1 (de) 1989-11-03 1991-05-08 Bayer Ag Halogenierte sulfonylaminocarbonyltriazolinone
DE3709574A1 (de) 1987-03-24 1988-10-06 Bayer Ag Substituierte triazolinone
DE4110795A1 (de) 1991-04-04 1992-10-08 Bayer Ag Sulfonylaminocarbonyltriazolinone mit ueber sauerstoff gebundenen substituenten
DE3916208A1 (de) 1989-05-18 1990-11-22 Bayer Ag Substituierte triazolone
DE4342190A1 (de) 1993-12-10 1995-06-14 Bayer Ag Verfahren und neue Zwischenprodukte zur Herstellung von Triazolinonen
DE4433968A1 (de) 1994-09-23 1996-03-28 Bayer Ag Verfahren zur Herstellung von Alkoxytriazolinonen
DE19627901A1 (de) 1996-07-11 1998-01-15 Bayer Ag Substituierte aromatische Carbonylverbindungen und ihre Derivate
US6444613B1 (en) 1999-03-12 2002-09-03 Hoechst Schering Agrevo Gmbh Defoliant
CA2746221A1 (en) 2008-12-08 2010-07-08 Sirtris Pharmaceuticals, Inc. Isoindolinone and related analogs as sirtuin modulators
US20100184815A1 (en) 2008-12-19 2010-07-22 Luehr Gary W Agonists of peroxisome proliferator activated receptor-alpha
EP2611785B1 (de) 2010-09-01 2014-06-04 Bayer Intellectual Property GmbH N-(tetrazol-5-yl)- und n-(triazol-5-yl)arylcarbonsäureamide und ihre verwendung als herbizide
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US20160251341A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted triazole compounds as serine protease inhibitors
CN106543139B (zh) 2015-09-17 2020-03-17 沈阳中化农药化工研发有限公司 一种三唑酮类化合物及其用途
US10968216B2 (en) 2016-10-27 2021-04-06 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
TW201945346A (zh) 2018-04-10 2019-12-01 德商拜耳廠股份有限公司 2,4,5-三取代的1,2,4-三唑酮之製備方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103006645A (zh) 2011-09-27 2013-04-03 华东理工大学 2-氨基苯并噻唑衍生物作为dhodh抑制剂的应用
JP2015523353A (ja) 2012-06-15 2015-08-13 グレンマーク・ファーマシューティカルズ・エスエー ｍＰＧＥＳ−１阻害剤としてのトリアゾロン化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [online]，2011年04月13日，[retrieved on 2021.08.23]，Retrieved from: STN，CAS登録番号：1278712-38-1等
HELENE MUNIER-LEHMANN ET AL，On Dihydroorotate Dehydrogenases and Their Inhibitors and Uses，JOURNAL OF MEDICINAL CHEMISTRY，2013年，vol. 56，3148 - 3167

Also Published As

Publication number Publication date
CR20190212A (es) 2019-06-24
US12486248B2 (en) 2025-12-02
UY37461A (es) 2018-05-31
CN110023302A (zh) 2019-07-16
US20200377472A1 (en) 2020-12-03
KR20190084954A (ko) 2019-07-17
US20200123129A1 (en) 2020-04-23
JP2019533694A (ja) 2019-11-21
BR112019008458A2 (pt) 2019-07-09
MX2019005009A (es) 2019-08-12
DOP2019000110A (es) 2019-05-31
CN110023302B (zh) 2022-07-26
CA3041643A1 (en) 2018-05-03
EP3532468B1 (en) 2022-03-23
CU24572B1 (es) 2022-01-13
UA123688C2 (uk) 2021-05-12
US20220135536A1 (en) 2022-05-05
AU2017351688B2 (en) 2022-02-03
ECSP19030002A (es) 2019-05-31
MX382665B (es) 2025-03-13
JOP20190094A1 (ar) 2019-04-25
TW201827414A (zh) 2018-08-01
US20230365524A1 (en) 2023-11-16
WO2018077923A1 (en) 2018-05-03
AU2017351688A1 (en) 2019-04-11
US20210188805A9 (en) 2021-06-24
CU20190045A7 (es) 2019-12-03
US10815215B2 (en) 2020-10-27
CO2019004137A2 (es) 2019-05-10
PH12019500932A1 (en) 2020-01-20
PE20191005A1 (es) 2019-07-15
NI201900041A (es) 2019-06-11
US11713304B2 (en) 2023-08-01
EP3532468A1 (en) 2019-09-04
TN2019000136A1 (en) 2020-10-05
IL266214B (en) 2021-10-31
CN115557907B (zh) 2024-12-06
US11130745B2 (en) 2021-09-28
IL266214A (en) 2019-06-30
CL2019001160A1 (es) 2019-09-13
CN115557907A (zh) 2023-01-03
GEP20217248B (en) 2021-04-26

Similar Documents

Publication Publication Date Title
CN110023302B (zh) 用作dhodh抑制剂的2,4,5-三取代的1,2,4-三唑酮
JP7747799B2 (ja) ４，５－縮環１，２，４－トリアゾロン
CA3137472A1 (en) Acyl sulfonamides for treating cancer
US12427153B2 (en) 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases
HK40086116A (zh) 用作dhodh抑制剂的2，4，5-三取代的1，2，4-三唑酮
HK40086116B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
HK40006139B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
HK40006139A (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
EA039707B1 (ru) 2,4,5-трехзамещенные 1,2,4-триазолоны, способы их получения, промежуточные соединения, фармацевтическая композиция и применение соединений для лечения гиперпролиферативного заболевания
HK40060627B (en) 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases
WO2020157236A1 (en) Pyridyl substituted dihydrooxadiazinones
HK40060627A (en) 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201023

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220602

R150 Certificate of patent or registration of utility model

Ref document number: 7084389

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250